Mode
Text Size
Log in / Sign up
Phase 2 N=50 Randomized Triple-blind Treatment

Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

Herniorrhaphy · Postoperative Pain · Inguinal Hernia

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores. — 2810.4; 3484.5 score on a scale*hour

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Bupivacaine Collagen Sponge (Drug); Placebo collagen Sponge (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
Innocoll
Primary completion
May 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores.
2810.4; 3484.5
SECONDARY
Sum of Pain Intensity (SPI) After Aggravated Movement (Cough)
996.3; 1270.4; 1021.8; 1186.7; 2018.2; 2457.2
SECONDARY
Sum of Pain Intensity (SPI) Using a Visual Analog Scale (VAS) When at Rest
741.6; 856.6; 754.7; 677.2; 1496.4; 1533.8
SECONDARY
Pain Intensity Visual Analog Pain Scale Scores Over Time After Aggravated Movement (Cough)
31.4; 73.4; 32.6; 60.6; 31.2; 57.0
SECONDARY
Pain Intensity VAS Scores Over Time at Rest
31.6; 73.4; 33.2; 60.6; 31.6; 57.0
SECONDARY
Mean Sum of Pain Intensity (SPI) Categorical Scores After Aggravated Movement
40.6; 45.6; 83.3; 90.2; 118.9; 128.8

Summary

This study will assess pain intensity for the first 72 hrs after after aggravated movement (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.

Eligibility Criteria

Inclusion Criteria

  • Man ≥ 18 years
  • Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.
  • Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free technique) to be performed according to standard surgical technique under general anesthesia.

Exclusion Criteria

  • Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.
  • Scheduled for bilateral inguinal herniorrhaphy.
  • Undergone a prior herniorrhaphy on the side scheduled for repair.
  • Undergone major surgery within 3 mos of the scheduled herniorrhaphy.
  • Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.
  • Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).
  • Used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01220024). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search